Custom Search


Monday 12 November 2007

Agreement between two methods for assessing bioequivalence of inhaled salbutamol.

By: Lavorini F, Geri P, Camiciottoli G, Pistolesi M, Fontana GA.

Pulm Pharmacol Ther 2007 Oct;(): [Epub ahead of print]

For inhaled medications, bioequivalence testing is becoming increasingly important owing to the availability of many inhalation devices. We evaluated agreement between the Finney bioassay and the E(max) model in the assessment of bioequivalence of salbutamol administered via a metered-dose inhaler with a spacer (pMDI+Volumatic) or via a dry-powder inhaler (Diskus) in asthmatic patients with methacholine-induced bronchoconstriction. Eighteen patients inhaled methacholine until FEV(1) decreased by approximately 35% of control. Following inhalation of placebo, 200 and 400mcg salbutamol through the pMDI+Volumatic or the Diskus, changes in FEV(1) were repeatedly measured over a 60-min observation period. Bioequivalence of salbutamol administered via the two inhalation devices was assessed by calculating the relative potency of each device by using the Finney 2-by-2 parallel regression analysis and the non-linear, E(max) model. Agreement between these methods in calculating relative potency was evaluated by using the Bland-Altman method. After salbutamol FEV(1) values were similar irrespective of the device employed, and greater (P<0.01) than those after placebo. However, assessment of relative potencies obtained with both the Finney (1.97, 90% CI 1.62-2.32) and the E(max) (2.25, 90% CI 1.90-2.60) methods revealed that twice the salbutamol dose was needed to reverse methacholine-induced bronchoconstriction when the drug was inhaled via the Diskus than via the pMDI+Volumatic. The mean difference in relative potency (-0.28, 90% CI -0.001 to -0.56) calculated with both methods did not significantly differ from zero, and none of the individual differences exceeded the limits of agreement. The Finney and the E(max) methods provide comparable results in the evaluation of bioequivalence of different salbutamol formulations. The pMDI+Volumatic is twice as efficient as the Diskus in lung delivery of salbutamol in asthma patients.

Use of this site is subject to the following terms of use